Notably, treatment with maraviroc, a CCR5-blocking agent, significantly enhanced trans infection of target CD4+ T cells by 8 days of co-culture when B lymphocytes were used, but this effect was not detected at day 12 (Figure 1A). The gene discussed is CCR5; the disease is infection.